GLP-1 scientists pass over again for the Nobel Prize

The Nobel Assembly at Karolinska Institutet announced on October 6, 2025, that the year's Nobel Prize in Physiology or Medicine would go to Mary E. Brunkow, Fred Ramsdell and Shimon Sakaguchi for their discoveries about peripheral immune tolerance, the system that keeps the immune response from attacking the body's own tissues ^[1]. The prize, worth 11 million Swedish kronor shared equally among the three, recognized work spanning three decades on a class of cells called regulatory T cells ^[1].

According to the Nobel committee, Sakaguchi identified these cells in 1995, showing the immune system had a previously unknown way of protecting the body from autoimmune disease beyond simply eliminating harmful cells in the thymus ^[1]. Brunkow and Ramsdell separately found in 2001 that a mutation in a gene they named Foxp3 explained why a certain mouse strain was prone to autoimmune illness, and that the same gene's human counterpart, when mutated, causes a serious autoimmune disease called IPEX ^[1]. Sakaguchi later connected the two findings, proving that Foxp3 controls development of the regulatory T cells he had described years earlier ^[1]. Olle Kämpe, chair of the Nobel Committee, said the discoveries explain "why we do not all develop serious autoimmune diseases" ^[1].

The committee's press release does not mention GLP-1 medicines, semaglutide, tirzepatide or the scientists associated with discovering or developing the GLP-1 hormone pathway ^[1]. The idea that GLP-1 researchers were "passed over again" reflects a broader pattern of speculation outside the official announcement; the source provided here does not itself discuss GLP-1 nominations, past or present, so specifics about who was nominated for GLP-1 work this year, or in prior years, are not established by the material available ^[1].

Why it matters for patients

For people taking or considering semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro, Zepbound) or orforglipron (Foundayo), this year's Nobel outcome has no direct bearing on drug approval, coverage, safety monitoring, or availability. Nobel Prizes recognize discoveries, often decades after the fact, and a prize decision does not change how a medicine is regulated or prescribed. Patients following news about GLP-1 drugs and the Nobel Prize should understand this is a story about scientific recognition and history, not about any change to the medicines themselves.

The 2025 prize does highlight a different area of immunology entirely. Regulatory T cells and the Foxp3 gene are tied to autoimmune disease and transplant medicine, according to the Nobel committee, and treatments based on this science are already in clinical trials for cancer and autoimmune conditions ^[1]. That is a separate line of medical research from the incretin-based science behind GLP-1 drugs, even though both fields involve major, ongoing scientific investigation.

What happens next

The Nobel committee's announcement on October 6, 2025, is final for this year's Physiology or Medicine prize; there is no appeals or reconsideration process in the source material ^[1]. The sources do not provide information on whether GLP-1-related discoveries were formally nominated for the 2025 prize or any future prize cycle, since Nobel nominations remain sealed for 50 years under the foundation's rules referenced in the release ^[1]. Future Nobel announcements, including in 2026, would be the next point at which GLP-1 science could again be discussed as a contender, though nothing in the available sources confirms or denies that possibility.